Rep. Pallone Inquires Into WEN Safety Concerns With Cosmetics Bill In The Works

In letters to Guthy-Renker and FDA leadership, House Democrat Frank Pallone probes for information regarding the safety of WEN Cleansing Conditioner, which he says has been linked to 17,000 complaints from consumers suffering hair loss and other adverse reactions. Cosmetics are "largely unregulated," according to the congressman, but he's working on legislation to reform the oversight framework.

Rep. Frank Pallone, D-N.J., seeks answers from FDA and Guthy-Renker LLC regarding widely alleged safety issues with WEN Cleansing Conditioner, which the congressman views as further evidence that cosmetics regulations need to be reformed.

Reports linking the WEN conditioner to hair loss and other adverse consumer experiences began surfacing in mass in 2014. According...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

US House Passes ‘Do Not Flush’ Legislation For Non-Flushable Personal Care Wipes

 

The US House of Representatives passes legislation requiring manufacturers of non-flushable wet wipes to label products as ‘non-flushable," a move endorsed by the Personal Care Products Council.

California Legislators Advance Bill To Ban Plastic Glitter, Abrasive Microbeads In Personal Care

 
• By 

Lawmakers in California heeded calls from industry to change proposed legislation to avoid a wider ban on microplastics in personal care products.

House Bill Aims to ‘Modernize’ US FDA’s Review Process For Sunscreens

 

Four co-chairs of the House of Representatives’ Skin Cancer Caucus have introduced the Safe Sunscreen Standards Act to direct FDA to establish clearer, ‘more flexible’ standards for evaluating sunscreen ingredients.

House Appropriators’ $3.2Bn For FDA In FY 2026 Includes More Non-User Fee Funds Than Requested

 

A US House bill would give the FDA $33.1m more in budget authority than requested by the Trump Administration for fiscal year 2026. The measure was sent to the full House Appropriations committee on a party-line vote.

More from Policy & Regulation

Cloudy Tariff Conditions Expected To Linger In US

 

White House announces president extends deadline he set in April for other countries to make new tariff deals from July 9 to Aug. 1, when the administration will start sending letters warning other countries that higher tariffs could take effect.

US FDA’s Tough Talk On Talc: Regulating In An Echo Chamber

 

An FDA “expert roundtable” on talc produced a new talking point on a potential drug safety risk, but the basis of that claim is difficult to determine.

ECHA Adds Two Cosmetic/Personal Care Silicones To REACH Candidate List

 

ECHA has added two silicone ingredients used in cosmetics and personal care products to the REACH Candidate List as they are persistent and have bioaccumulative properties, requiring companies to notify customers and update safety data sheets if concentrations exceed 0.1%.